Publication & Citation Trends
Publications
0 total
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia OA
Cited by 32
Semantic Scholar
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis OA
Cited by 36
Semantic Scholar
CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study OA
Cited by 5
Semantic Scholar
Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study
Cited by 14
Semantic Scholar
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome OA
Cited by 49
Semantic Scholar
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow OA
Cited by 192
Semantic Scholar
Analyses of the MEC1 DNA Damage Pathway in Saccharomyces cerevisiae OA
Cited by 0
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(15)
Acute Myeloid Leukemia Research
(4)
DNA Repair Mechanisms
(3)
Neutropenia and Cancer Infections
(2)
bioluminescence and chemiluminescence research
(2)
Affiliations
Louisiana State University
Louisiana State University Agricultural Center
AbbVie (United States)
Xencor (United States)